Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tani, M
Right arrow Articles by Zinzani, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tani, M
Right arrow Articles by Zinzani, P.
Haematologica, Vol 90, Issue 9, 1283-1284
Copyright © 2005 by Ferrata Storti Foundation

Clinical Trial, Phase II

Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma

M Tani, M Fina, L Alinari, V Stefoni, M Baccarani, and PL Zinzani

Between July 2003 and March 2004, nine patients with pretreated mycosis fungoides were enrolled into a phase II trial and were treated with temozolomide. The overall response rate was 33%. Further studies are needed to test the efficacy of temozolomide, alone or in combination in earlier stages of this disease.


This article has been cited by other articles:


Home page
 Arch DermatolHome page
G. Quereux, S. Marques, J.-M. Nguyen, C. Bedane, M. D'incan, O. Dereure, E. Puzenat, A. Claudy, L. Martin, P. Joly, et al.
Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sezary Syndrome
Arch Dermatol, June 1, 2008; 144(6): 727 - 733.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.